© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 80200 refers to the measurement of tobramycin levels in the blood. Tobramycin is classified as an injectable aminoglycoside antibiotic that is primarily utilized in the treatment of severe or serious bacterial infections. The measurement of tobramycin levels is critical due to the drug's potential side effects, which include auditory, vestibular, and renal toxicity. Monitoring these levels helps ensure that the drug is administered safely and effectively. The testing can be performed at various times, including random, peak, and trough levels. A random sample can be collected at any time, while peak and trough levels are specifically time-dependent. Typically, trough levels are drawn 5 to 90 minutes before the administration of the drug, either through intravenous infusion or intramuscular injection. Conversely, peak levels are collected 30 minutes after the completion of an intravenous infusion or 30 to 90 minutes following an intramuscular injection. The blood sample required for this test is obtained through a venipuncture, which is a separately reportable procedure. The analysis of the blood serum is conducted using a method known as fluorescence polarization immunoassay, which allows for accurate measurement of the tobramycin concentration in the bloodstream.
© Copyright 2025 Coding Ahead. All rights reserved.
The measurement of tobramycin levels is indicated in the following scenarios:
The procedure for measuring tobramycin levels involves several key steps:
After the blood sample has been collected and sent for analysis, there are no specific post-procedure care requirements for the patient related to the blood draw itself. However, it is important for healthcare providers to monitor the patient for any signs of toxicity associated with tobramycin, especially if the levels are found to be outside the therapeutic range. The results of the tobramycin level tests will guide further treatment decisions, including dosage adjustments or the need for additional monitoring. Regular follow-up may be necessary, particularly in patients receiving ongoing therapy with tobramycin, to ensure continued safety and efficacy of the treatment.
| Short Descr | ASSAY OF TOBRAMYCIN |
| Medium Descr | DRUG SCREEN QUANTITATIVE TOBRAMYCIN |
| Long Descr | Tobramycin |
| Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) |
| Global Days | XXX - Global Concept Does Not Apply |
| PC/TC Indicator (26, TC) | 9 - Not Applicable |
| Multiple Procedures (51) | 9 - Concept does not apply. |
| Bilateral Surgery (50) | 9 - Concept does not apply. |
| Physician Supervisions | 09 - Concept does not apply. |
| Assistant Surgeon (80, 82) | 9 - Concept does not apply. |
| Co-Surgeons (62) | 9 - Concept does not apply. |
| Team Surgery (66) | 9 - Concept does not apply. |
| Diagnostic Imaging Family | 99 - Concept Does Not Apply |
| CLIA Waived (QW) | No |
| APC Status Indicator | Conditionally packaged laboratory tests |
| Type of Service (TOS) | 5 - Diagnostic Laboratory |
| Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) |
| MUE | 2 |
| CCS Clinical Classification | 235 - Other Laboratory |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. |
| 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. |
| GW | Service not related to the hospice patient's terminal condition |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. |
| 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. |
| XE | Separate encounter, a service that is distinct because it occurred during a separate encounter |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Changed | Medium description changed per AMA 2013 corrections document dated January 25, 2013. |
| 1993-01-01 | Added | First appearance in code book in 1993. |
|
Code
|
Description
|
|---|---|
| 250.00 | Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled |
| 250.01 | Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled |
| 250.02 | Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled |
| 250.03 | Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled |
| 250.40 | Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled |
| 250.41 | Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled |
| 250.42 | Diabetes with renal manifestations, type II or unspecified type, uncontrolled |
| 250.43 | Diabetes with renal manifestations, type I [juvenile type], uncontrolled |
| 250.50 | Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled |
| 250.51 | Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled |
| 250.52 | Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled |
| 250.53 | Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled |
| 250.60 | Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled |
| 250.61 | Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled |
| 250.62 | Diabetes with neurological manifestations, type II or unspecified type, uncontrolled |
| 250.63 | Diabetes with neurological manifestations, type I [juvenile type], uncontrolled |
| 250.70 | Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled |
| 250.71 | Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled |
| 250.72 | Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled |
| 250.73 | Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled |
| 250.80 | Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled |
| 250.81 | Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled |
| 250.82 | Diabetes with other specified manifestations, type II or unspecified type, uncontrolled |
| 250.83 | Diabetes with other specified manifestations, type I [juvenile type], uncontrolled |
| 250.90 | Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled |
| 250.91 | Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled |
| 250.92 | Diabetes with unspecified complication, type II or unspecified type, uncontrolled |
| 250.93 | Diabetes with unspecified complication, type I [juvenile type], uncontrolled |
| 278.01 | Morbid obesity |
| 536.3 | Gastroparesis |
| 564.2 | Postgastric surgery syndromes |
| 780.4 | Dizziness and giddiness |
| 783.5 | Polydipsia |
| 788.41 | Urinary frequency |
| 788.42 | Polyuria |
| 791.9 | Other nonspecific findings on examination of urine |
| 960.8 | Poisoning by other specified antibiotics |
| 996.59 | Mechanical complication due to other implant and internal device, not elsewhere classified |
| 996.69 | Infection and inflammatory reaction due to other internal prosthetic device, implant, and graft |
| 996.79 | Other complications due to other internal prosthetic device, implant, and graft |
| 997.4 | Digestive system complications [added] |
| 998.59 | Other postoperative infection |
| 998.89 | Other specified complications of procedures not elsewhere classified |
| V45.86 | Bariatric surgery status |
| V53.50 | Fitting and adjustment of intestinal appliance and device |
| V53.59 | Fitting and adjustment of other gastrointestinal appliance and device |
| V58.62 | Long-term (current) use of antibiotics |
| V72.60 | Laboratory examination, unspecified |
| V72.69 | Other laboratory examination |
| No matching codes found | |